Medicine Is Making
Real Progress

FDA approval of a new orally disintegrating tablet offers chronic myeloid leukemia patients greater flexibility in treatment options.

FDA approval of a new orally disintegrating tablet formulation offers patients greater treatment flexibility for chronic myeloid leukemia.

Daraxonrasib represents a significant new treatment option that could improve outcomes for pancreatic cancer patients.

New bladder cancer drug helps individual patient achieve improved outcomes and quality of life.

Medical equity breakthroughs are being recognized and celebrated at major science competitions.

Ochsner Health showcases promising biomedical breakthroughs and innovative clinical trial approaches advancing patient care.

Drug-filled nanofibers represent a promising new approach to delivering treatment directly to brain cancer tumors.

InnoCare's new drug application acceptance marks progress toward bringing a new treatment to patients.

FDA approves Hepcludex as the first-ever treatment for hepatitis D, offering hope to patients with limited options.

World's first Class III approval for breakthrough medical imaging AI brings advanced diagnostic capabilities to clinical practice.

A new targeted cancer therapy receives priority review status, accelerating its path to patients in need.

UT MD Anderson shares latest cancer research breakthroughs advancing patient treatment options.

A vitamin D analog from Salk Institute successfully disarms pancreatic cancer's defenses in clinical trials, moving from lab to patient treatment.

A father celebrates his son's ability to access a new life-changing drug, bringing hope to families.

Japanese iPS organoid research is driving significant advances in regenerative medicine.

FDA approval of an innovative kidney stone treatment developed through biomedical engineering offers patients a new solution.

FDA approval of new ovarian cancer treatments expands therapeutic options for patients.

New medication for Tourette Syndrome shows promise in Phase III clinical trials.

The Miami CFAR Symposium showcases major breakthroughs in HIV treatment and cure research that are transforming the fight against the disease.

A novel nightly pill for sleep apnea has shown strong trial results and is being fast-tracked toward FDA approval.

First-ever weekly basal insulin approved by FDA simplifies diabetes management for patients.

Datroway received FDA approval as the first TROP2-directed antibody drug for metastatic triple-negative breast cancer treatment.

AI is unlocking life-saving treatments for diseases previously considered incurable.

Retatrutide clinical trial shows dramatic weight loss results, offering a promising new treatment option.

New understanding of how cancer develops during cell division could lead to improved prevention strategies.

Vertex's pain relief drug suzetrigine advances with Health Canada review for treating moderate-to-severe acute pain.

Lilly's experimental weight loss drug shows significant results, helping patients lose substantial amounts of weight.

Five FDA first-in-class drug approvals in 2026 bring innovative new treatment mechanisms to patients.

Discovery of a previously unknown circulatory system bridges traditional and modern medical understanding.

Bayer's KERENDIA receives FDA priority review for treating kidney disease in adults with type 2 diabetes.

Scientists have developed an innovative bone-healing material from wool, offering a promising new option for patients recovering from bone injuries.

Strategic pilot funding at Columbia University is accelerating multiple cancer research breakthroughs.

Researchers have discovered how light can activate tiny molecules for potential medical applications, opening new therapeutic possibilities.

FDA approves a new blood pressure medication providing patients with an additional hypertension management option.

Mental health awareness and community discussion promotes better patient care.

FDA approval of the first aldosterone synthase inhibitor provides a new treatment option for hypertension patients.

AstraZeneca's new blood pressure pill opens a new drug class for hypertension treatment.

AstraZeneca's blood pressure drug receives US approval, offering patients another treatment option.

A new fundraising campaign supports the Olivia Newton-John Cancer Research Institute's important cancer research initiatives.

University of Miami researchers share breakthroughs in heart, vision, and cancer research.

Innovative cancer immunotherapy receives regulatory approval for clinical development.

BeOne receives FDA approval for a new mantle cell lymphoma therapy, establishing an entirely new class of treatment options for patients.

First major stomach cancer drug approved for NHS use in a decade offers patients a significant therapeutic advance.

FDA approvals of Beqalzi and Inqovi represent important new treatment options for patients with mantle cell lymphoma and blood cancers.

Regenxbio's positive new data brings hope closer to patients with Duchenne muscular dystrophy seeking gene therapy treatment.

FDA advances personalized, patient-centered care approaches offering more tailored treatment options.

America's national laboratories have achieved 75 breakthroughs advancing scientific progress.

FDA approval expands treatment options available to Alzheimer's disease patients.

A new blood pressure medication offers patients another therapeutic option.

A new medical breakthrough offers hope in the fight against cancer detection and treatment.

Kelun-Biotech's innovative PD-1 x VEGF bispecific antibody receives investigational approval for cancer treatment.

Texas A&M researchers achieved a breakthrough in medical device sterilization that could improve safety and efficiency in healthcare.

A pancreatic cancer patient is finding renewed hope through breakthrough treatments that are extending and improving her life.

First in-body CRISPR gene therapy shows clinical success and moves toward FDA approval, representing a major breakthrough in genetic medicine.

A chemist's cancer research breakthrough earns national recognition for advancing the field.

A nature-inspired adhesive breakthrough could revolutionize bone repair and surgical procedures.

A biotech company's first FDA-approved drug represents progress in bringing new treatments to market.

Molecular switch discovery opens promising new therapeutic avenue for treating bone diseases.

AI drug trial platform expansion to US market promises to improve clinical trial efficiency and patient recruitment.